CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells

For patients carrying BRCA1 mutations, at least one‐third develop triple negative breast cancer (TNBC). Not only is TNBC difficult to treat due to the lack of molecular target receptors, but BRCA1 mutations (BRCA1m) also result in chemotherapeutic resistance, making disease recurrence more likely. A...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Bioeng Transl Med
Главные авторы: Mintz, Rachel L., Lao, Yeh‐Hsing, Chi, Chun‐Wei, He, Siyu, Li, Mingqiang, Quek, Chai Hoon, Shao, Dan, Chen, Boyuan, Han, Jing, Wang, Sihong, Leong, Kam W.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2020
Предметы:
Rapid Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971465/
https://ncbi.nlm.nih.gov/pubmed/31989039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/btm2.10152
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы